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Abstract 52 
The melanocortin 2 receptor accessory protein (MRAP) was originally 53 
discovered to be an essential co-receptor for the ACTH receptor/melanocortin 54 
2 receptor, and it physically interacts with this receptor and is required for 55 
receptor trafficking and ligand binding.  A related molecule, MRAP2, is mainly 56 
expressed in the CNS and appears to have a role with the melanocortin 4 57 
receptor.  Consistent with this is the observation that a massively obese 58 
phenotype develops when the Mrap2 gene is deleted in mice.  However, the 59 
characteristics of this phenotype differ from those of Mc4r deleted mice, and 60 
suggest that an additional role, possibly resulting from an interaction with 61 
other receptors is possible.  In support of this, a functional interaction with the 62 
prokineticin receptors was recently reported.  Evidence for other receptor 63 
interactions and aspects of the tissue distribution of MRAP and MRAP2 gene 64 
expression may indicate that these accessory proteins have a wider role than 65 
with the melanocortin receptors alone.    66 
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 88 
Introduction 89 
Enormous financial and technical efforts are being expended in the drive to 90 
develop new and better drugs – many of which will be targeted at G protein-91 
coupled receptors (GPCR).  Massive small molecule library screening 92 
requires the availability of a target that most closely resembles the 93 
physiological target, and yet our understanding of the subtle regulatory factors 94 
that may influence these GPCRs is often not adequately represented in these 95 
screening procedures.  It becomes particularly important therefore that efforts 96 
to properly understand any such receptor-associated factors are pursued.  97 
This view is well illustrated by considering the case of the melanocortin 98 
receptor accessory proteins (MRAPs). 99 
 100 
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The discovery of MRAP 101 
 102 
An intact pituitary-adrenal axis is essential for normal healthy existence in 103 
mammals, and yet is surprisingly dependent on a number of unique 104 
components encoded by single genes such as the proopiomelanocortin gene 105 
and the receptor for adrenocorticotropin (ACTH). 106 
   107 
The ACTH receptor – properly known as the melanocortin 2 receptor (MC2R) 108 
was cloned in 1992, and it was immediately apparent that it was very difficult 109 
to express a functional receptor in transfected cells.  In their original paper 110 
Mountjoy et al (1992) only reported MC2R expression in a cell line that 111 
expressed an endogenous MC1R.  Using a green fluorescent protein-tagged 112 
MC2R, we demonstrated that the hybrid protein seemed to be retained in the 113 
endoplasmic reticulum and failed to reach the cell surface (Noon et al, 2002).  114 
Significantly, cell lines derived from the murine adrenocortical tumour Y1 line 115 
which had developed unresponsiveness to ACTH action were found to be 116 
capable of expressing the transfected MC2R (Yang et al, 1997).  This 117 
evidence suggested the existence of one or more adrenal-specific accessory 118 
factors that were required for receptor expression. 119 
 120 
This hypothesis was shown to be correct in 2005 with the identification of a 121 
novel genetic cause of human ACTH insensitivity.  Metherell et al, 2005 122 
described a number of families in which a gene encoding a small single 123 
transmembrane domain protein was mutated.  Co-transfection of this gene 124 
with the MC2R enabled a fully functional MC2R to be transported to the 125 
plasma membrane and to respond to ACTH stimulation by generating a cAMP 126 
signal.  We named this the melanocortin 2 receptor accessory protein (MRAP) 127 
although, as will become apparent, this is occasionally and more helpfully 128 
referred to as MRAP1 and this terminology is used henceforth. 129 
 130 
MRAP1 was most strongly expressed in adrenal tissues and cells, as well as 131 
in the gonad and adipose tissue.  Human MRAP1 existed as one of two splice 132 
variants – MRAP1 α and β that had distinct 3’ ends encoding different C-133 
termini.  We found MRAP1 existed as a very stable dimer that was relatively 134 
resistant to dissociation by detergents and reducing agents (Cooray et al, 135 
2008).  Remarkably, Sebag & Hinkle (2007) demonstrated using a number of 136 
techniques that this was an antiparallel homodimer in which one N-terminus 137 
was extracellular and the other intracellular.  This structure is represented in 138 
the Figure. This seems to be a unique phenomenon in eukaryotic biology – 139 
although this topology has probably only very rarely been sought in other 140 
dimeric proteins.   141 
 142 
It now appears that MRAP1 plays several key roles in expression of the 143 
MC2R.  The MRAP1 dimer complexes with the receptor at the endoplasmic 144 
reticulum and this event is required for the receptor to be trafficked to the cell 145 
surface.  During processing MRAP1 may also influence MC2R glycosylation 146 
(Kay et al, 2015).  At the cell surface MRAP1 is required for ACTH to generate 147 
a G protein mediated signal (predominantly via Gαs), and this is probably 148 
because the N-terminus of MRAP1 contributes to the recognition and binding 149 
of ACTH (Malik et al, 2015).  150 
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 151 
MRAP2 152 
In our original paper describing MRAP1, we also pointed to the existence of a 153 
gene predicted to encode a related protein, which we called MRAP2 on the 154 
basis of its relatedness to MRAP1 (Metherell et al, 2005).  As with MRAP, 155 
MRAP2 also naturally exists as an antiparallel homodimer but with a distinct 156 
tissue expression pattern principally in many areas of the CNS (Chan et al, 157 
2009; Asai et al, 2013; Chaly et al, 2016).  We demonstrated that MRAP2 158 
interacted with all five of the melanocortin receptors in transfected cells (as 159 
does MRAP1) (Chan et al, 2009).  MRAP2 supports trafficking of MC2R, 160 
although ACTH responsiveness is markedly weaker, such that substantially 161 
greater, supraphysiological concentrations of ACTH are required to activate 162 
this receptor (Gorrigan et al, 2011).  Both MRAPs partially inhibited the 163 
signaling of the MC1R, MC3R, MC4R and MC5R (Chan et al, 2009).  In the 164 
case of the inhibition of the MC5R there is evidence to suggest that MRAP2 165 
inhibits MC5R homodimerisation (Sebag & Hinkle, 2009).  Agulleiro et al 166 
(2013) demonstrated that the zebrafish MRAP2a, but not the related 167 
MRAP2b, was able to increase the responsiveness of Zf MC4R to ACTH 168 
without altering the MSH response and it is conceivable that modulation of 169 
agonist selectivity by MRAP2 could occur with other receptors or in other 170 
species. 171 
 172 
Since both MRAP2 and the MC4R are expressed in the paraventricular 173 
nucleus of the hypothalamus, where it is well established that the MC4R has a 174 
key role in regulating satiety, the possibility that MRAP2 has a part to play in 175 
MC4R function and appetite regulation arises.   Asai et al (2013) 176 
demonstrated that under certain transfection conditions, in which a 6:1 ratio of 177 
MRAP2 to MC4R expression vector was used, MRAP2 reduced the 178 
constitutive activity of the MC4R and enhanced the maximal effect of α-MSH 179 
stimulation.  As this results in a greater change in signal for a given change in 180 
agonist dosage, this can be interpreted as “sensitizing” the MC4R to agonist.  181 
It is notable that the effect on constitutive activity was similar to a non-182 
significant trend previously observed by Chan et al (2009), although this 183 
directly contrasted with the opposite effect – an increase in constitutive activity 184 
in the presence of MRAP2 - described by Kay et al, 2015.  These contrasts 185 
should prompt caution in interpreting heterologous cell transient expression 186 
studies, particularly when discrepant concentrations of expression vector are 187 
required to demonstrate a result. 188 
 189 
Arguably, a more physiological examination of this hypothesis is provided by 190 
the development of the MRAP2 gene deleted mouse (Mrap2-/-) which 191 
exhibited a severe obesity phenotype (Asai et al, 2013).  A hypomorph Mrap2 192 
mouse generated using a different strategy and only expressing a fraction of 193 
normal Mrap2 mRNA resulted in a very similar phenotype (Novoselova et al, 194 
2016), as did deletion of Mrap2 exclusively in the Sim1 neurones of the 195 
paraventricular nucleus – implying that the mechanism was dependent solely 196 
on these neurons in the hypothalamus (Asai et al, 2013).  These observations 197 
are highly suggestive of a vital role of MRAP2 with the MC4R.   198 
 199 
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However closer examination of the data shows that the phenotypes of the 200 
Mc4r -/- mice and the Mrap2 -/- mice are distinct.  In particular, the synthetic 201 
MC4R agonist, MTII, is fully effective in Mrap2 -/- animals in contrast to its 202 
complete inactivity in Mc4r -/- mice (Asai et al, 2013), implying that the α-MSH 203 
induced satiety pathways are fully functional in Mrap2 knockout animals.  204 
Mc4r-/- mice are hyperphagic and show reduced energy expenditure and 205 
insulin resistance, whereas no disturbance of food intake, energy expenditure 206 
or insulin and glucose regulation was seen in the Mrap2-/- mice.  In fact male 207 
hypomorphic Mrap2 mice show increased beam breaking activity compared to 208 
wild type littermates.  Bone mineral density is unchanged in hypomorphic 209 
Mrap2 mice in contrast to increased density seen in Mc4r-/- animals 210 
(Novoselova et al, 2016).  These distinctions are summarized in Table 1.   211 
 212 
Thus the evidence seems to suggest that although MRAP2 has a significant 213 
role in body weight maintenance, and that this role is delivered through the 214 
paraventricular nucleus of the hypothalamus, any influence on MC4R function 215 
is probably complicated by a role with other appetite regulating pathways. 216 
 217 
 218 
Are the MRAPs promiscuous? 219 
Phylogenetic studies demonstrate fairly conclusively that MRAP2 is the 220 
ancestral gene, being identifiable in the sea lamprey (Petromyzon marinus)  221 
Evidence for MRAP first arises at the time of the development of the teleosts  222 
(Takifugu Rubripes) or possibly in elasmobranchs including the elephant 223 
shark (Callorhinchus milii), and from this time both genes exist with a key role 224 
for MRAP in supporting MC2R function emerging by the time of the evolution 225 
of the zebrafish (Danio rerio) (Vastermark & Schioth, 2011).  It is conceivable 226 
that although MRAP seems to have a vital role with the MC2R in mammals, 227 
there is no strong evidence that MRAP2 functions are restricted to the 228 
melanocortin receptors.   229 
 230 
In support of the idea of a broader role for the MRAPs it is notable that Chan 231 
et al showed that MRAP2 interacted with the β2-adrenergic receptor in 232 
transfected cells without apparently influencing its signaling capacity, but not 233 
with the AT1 angiotensin receptor (Chan et al, 2009).  More recently, Chaly et 234 
al (2016) reported an interaction between the prokineticin 1 and 2 receptors 235 
(PKR1, PKR2) and MRAP2, and an inhibitory effect of MRAP2 when 236 
expressed in vitro with these receptors (although a 10:1 ratio of MRAP2 to 237 
PKR1 or PKR2 expression vector was used).  These findings are particularly 238 
interesting in the light of the Mrap2 knockout mouse studies.  PKR2 is 239 
expressed in the arcuate nucleus and mediates a satiety effect that Chaly et 240 
al showed is independent of the MC4R anorectic effect.  If MRAP2 has a 241 
physiological role in suppressing the PKR1 signal, one might expect the 242 
Mrap2 knockout animal to show a lean phenotype, but it is argued that when 243 
this action is compounded with the potent reduction in satiety resulting from 244 
impaired MC4R action, the distinct phenotype observed by Asai et al and 245 
Novoselova et al results.  Attractive as this hypothesis is, some questions 246 
remain, such as why the Mrap2 knockout phenotype seems to arise from the 247 
paraventricular nucleus (as shown by the Sim1 conditional knockout), 248 
whereas the PKR1 action occurs in the arcuate nucleus. 249 
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 250 
Thus evidence is beginning to emerge that MRAP2 may be more 251 
promiscuous than originally thought in having a range of receptor partners.  252 
Humans with a defective MRAP1 gene exhibit a very clear adrenal failure 253 
phenotype without other consistent clinical problems.  However, MRAP1 is 254 
expressed in tissues with little or no MC2R expression and the possibility of 255 
non-MC2R consequences may have to await the characterization of the Mrap 256 
-/- mouse. 257 
 258 
This evidence of an expanding and more promiscuous role for the MRAPs 259 
resembles the way in which the RAMP proteins were initially believed to be 260 
calcitonin-like receptor specific accessory proteins, but which are now well-261 
recognized to have a broader range of functions with several members of the 262 
Class 2 GPCRs (Hay et al, 2006).  Further dissection of the Mrap2 knockout 263 
model, the development and characterization of an Mrap1 knockout and 264 
careful in vitro identification of further interacting partners of the MRAPs may 265 
reveal novel aspects of physiology, which may be important in supporting 266 
efforts to develop drugs that target these pathways. 267 
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Figure Legend 
 
Schematic representation of the antiparallel topology of the MRAP proteins that 
result in one N-terminus and one C-terminus being presented on each surface of the 
plasma membrane for each dimer. 
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Table 1 
Comparison of the metabolic phenotype of the Mc4r-/- and Mrap2-/- mice. 
 
 
Parameter    Mc4r-/- mouse    Mrap2-/- mouse 
 
Weight    ++++      +++ 
 
Hyperphagia    >20%      No change 
 
Energy expenditure         No change 
 
Movement    No change      
 
Insulin    +++      No change 
 
Glucose tolerance    at 10 - 14 weeks    No difference 12 – 28 weeks 
 
Response to MTII   No response     Reduced feeding - same as wild type 
 
Bone density           No change 
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Schematic representation of the antiparallel topology of the MRAP proteins that result in one N-terminus and 
one C-terminus being presented on each surface of the plasma membrane for each dimer.  
This structure is represented  
254x190mm (72 x 72 DPI)  
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